#AS­CO22: Gilead’s Trodelvy shows slim ben­e­fit in com­mon form of breast can­cer

In March, Gilead drew ire from an­a­lysts for re­leas­ing an up­beat Q&A with­out any hard da­ta for its lat­est Trodelvy tri­al, which put in­to ques­tion whether the big biotech’s drug would be ef­fec­tive in one of the most com­mon forms of breast can­cer.

Now, the da­ta are fi­nal­ly here, show­ing that Trodelvy slight­ly out­did stan­dard care in an on­go­ing Phase III study with over 500 pa­tients who have HR+/HER2- metasta­t­ic breast can­cer. All of the pa­tients had al­ready been treat­ed with en­docrine ther­a­py and more than half had three or more pre­vi­ous chemother­a­py reg­i­mens.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER